COSMO Pharmaceuticals shares fell to 57.90 Swiss francs following a sharp correction from earlier highs, despite positive trial data for the company’s topical hair-loss treatment and financial performance. The stock surged to 124.50 francs between December 2025 and March 2026 after the Milan-based biotechnology company announced trial results for its 5 percent Clascoterone topical solution, before sliding below its initial announcement price.
Clinical Trial Results and Regulatory Timeline for Clascoterone
The Phase III clinical trial program for the 5 percent Clascoterone topical solution achieved statistically significant endpoints in target hair count. According to company disclosures released in December 2025 and April 2026, two separate studies showed relative improvements of 539 percent and 168 percent respectively over placebos, alongside a demonstrated safety profile supporting long-term use. Patients treated continuously showed sustained hair growth through month twelve, whereas patients switched to a placebo at month seven experienced a reversal of treatment gains.
Following these findings, COSMO is advancing regulatory filings in the United States and Europe. The company plans to submit a New Drug Application to the U.S. Food and Drug Administration in early 2027, with European filings expected during the same year. Kepler Cheuvreux analyst Nicolas Paulliac noted in a July note that completing these regulatory submissions represents a vital catalyst for a potential stock re-evaluation, contingent upon publishing the complete efficacy dataset to support upcoming licensing agreements.
Market Competition and Financial Standing
COSMO operates within a broader hair-loss treatment sector estimated by Jefferies analysts to reach a substantial global market value, with peak sales for the company’s specific therapy potentially hitting significant figures provided an effective distribution partner is secured before the end of the year. Competitors include American biotechnology firms Absci and Veradermics, which advanced their own pipeline treatments and saw shares rise by 180 percent over the year, alongside Novo Nordisk's entry into the hair-loss therapy market.
In addition to dermatology developments, COSMO completed patient enrolment for a Phase II clinical trial evaluating a novel enema formulation of the active ingredient rifamycin. Announced on May 18, 2026, the study tests 77 patients across 24 European sites to assess safety and efficacy in treating distal ulcerative colitis and proctitis, with initial results anticipated in autumn 2026.
Worth a look
- HSE Winter Vaccination Programme Underway for Flu and COVID-19
- Daily strawberry consumption reduces menstrual pain, study finds
- Wall Street money takes back over from small investors as driving force of the stock market (newsylist.com)
- Why Larry Ellison's Scrapped $7.5 Billion Stock Sale Was Never a Secret (daybreakwire.com)